Literature DB >> 23371797

Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer.

Bradley J Barney1, Xin Shelley Wang, Charles Lu, Zhongxing Liao, Valen E Johnson, Charles S Cleeland, Tito R Mendoza.   

Abstract

PURPOSE: Patient-reported outcomes (PROs) have been found to be significant predictors of clinical outcomes such as overall survival (OS), but the effect of demographic and clinical factors on the prognostic ability of PROs is less understood. Several PROs derived from the 12-item Short-Form Health Survey (SF-12) and M. D. Anderson Symptom Inventory (MDASI) were investigated for association with OS, with adjustments for other factors, including performance status.
METHODS: A retrospective analysis was performed on data from 90 patients with stage IV non-small cell lung cancer. Several baseline PROs were added to a base Cox proportional hazards model to examine the marginal significance and improvement in model fit attributable to the PRO: mean MDASI symptom interference level; mean MDASI symptom severity level for five selected symptoms; SF-12 physical and mental component summaries; and the SF-12 general health item. Bootstrap resampling was used to assess the robustness of the findings.
RESULTS: The MDASI mean interference level had a significant effect on OS (p = 0.007) when the model was not adjusted for interactions with other prognostic factors. Further exploration suggested the significance was due to an interaction with performance status (p = 0.001). The MDASI mean symptom severity level and the SF-12 physical component summary, mental component summary, and general health item did not have a significant effect on OS.
CONCLUSIONS: Symptom interference adds prognostic information for OS in advanced lung cancer patients with poor performance status, even when demographic and clinical prognostic factors are accounted for.

Entities:  

Mesh:

Year:  2013        PMID: 23371797      PMCID: PMC3724766          DOI: 10.1007/s11136-013-0356-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  28 in total

1.  Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy.

Authors:  M Ikeda; S Okada; K Tokuuye; H Ueno; T Okusaka
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

2.  A bootstrap resampling procedure for model building: application to the Cox regression model.

Authors:  W Sauerbrei; M Schumacher
Journal:  Stat Med       Date:  1992-12       Impact factor: 2.373

3.  Bootstrap investigation of the stability of a Cox regression model.

Authors:  D G Altman; P K Andersen
Journal:  Stat Med       Date:  1989-07       Impact factor: 2.373

4.  Relationship between deficits in overall quality of life and non-small-cell lung cancer survival.

Authors:  Jeff A Sloan; Xinghua Zhao; Paul J Novotny; Jason Wampfler; Yolanda Garces; Matthew M Clark; Ping Yang
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

Review 5.  Electronic toxicity monitoring and patient-reported outcomes.

Authors:  Ethan M Basch; Bryce B Reeve; Sandra A Mitchell; Stephen B Clauser; Lori Minasian; Laura Sit; Ram Chilukuri; Paul Baumgartner; Lauren Rogak; Emily Blauel; Amy P Abernethy; Deborah Bruner
Journal:  Cancer J       Date:  2011 Jul-Aug       Impact factor: 3.360

6.  Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

Authors:  C S Cleeland; T R Mendoza; X S Wang; C Chou; M T Harle; M Morrissey; M C Engstrom
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

7.  Regression modelling strategies for improved prognostic prediction.

Authors:  F E Harrell; K L Lee; R M Califf; D B Pryor; R A Rosati
Journal:  Stat Med       Date:  1984 Apr-Jun       Impact factor: 2.373

8.  Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Authors:  Chantal Quinten; Corneel Coens; Murielle Mauer; Sylvie Comte; Mirjam A G Sprangers; Charles Cleeland; David Osoba; Kristin Bjordal; Andrew Bottomley
Journal:  Lancet Oncol       Date:  2009-08-18       Impact factor: 41.316

9.  Prognostic factors associated with brain metastases from epithelial ovarian carcinoma.

Authors:  T-J Kim; S Song; C K Kim; W Y Kim; C H Choi; J-H Lee; J-W Lee; D-S Bae; B-G Kim
Journal:  Int J Gynecol Cancer       Date:  2007-04-18       Impact factor: 3.437

10.  Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.

Authors:  Jong Gwang Kim; Baek-Yeol Ryoo; Yeon Hee Park; Bong-Seog Kim; Tae-You Kim; Young-Hyuck Im; Yoon-Koo Kang
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-12       Impact factor: 3.333

View more
  8 in total

1.  Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma.

Authors:  Nina Shah; Qiuling Shi; Sergio Giralt; Loretta Williams; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Charles S Cleeland; Xin Shelley Wang
Journal:  Qual Life Res       Date:  2017-12-19       Impact factor: 4.147

2.  Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review.

Authors:  Kuan Liao; Tianxiao Wang; Jake Coomber-Moore; David C Wong; Fabio Gomes; Corinne Faivre-Finn; Matthew Sperrin; Janelle Yorke; Sabine N van der Veer
Journal:  BMC Cancer       Date:  2022-10-19       Impact factor: 4.638

Review 3.  Patient reported outcomes in oncology: changing perspectives-a systematic review.

Authors:  Augusta Silveira; Teresa Sequeira; Joaquim Gonçalves; Pedro Lopes Ferreira
Journal:  Health Qual Life Outcomes       Date:  2022-05-21       Impact factor: 3.077

4.  Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Annette McDonough; Diane L Carroll
Journal:  J Pain Symptom Manage       Date:  2015-08-20       Impact factor: 3.612

5.  Prognostic Significance of Patient-Reported Outcomes in Cancer.

Authors:  Kathleen Kerrigan; Shiven B Patel; Benjamin Haaland; Dominik Ose; Anna Weinberg Chalmers; Tyler Haydell; Neal J Meropol; Wallace Akerley
Journal:  JCO Oncol Pract       Date:  2020-01-09

6.  Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy.

Authors:  Kea Turner; Naomi C Brownstein; Zachary Thompson; Issam El Naqa; Yi Luo; Heather S L Jim; Dana E Rollison; Rachel Howard; Desmond Zeng; Stephen A Rosenberg; Bradford Perez; Andreas Saltos; Laura B Oswald; Brian D Gonzalez; Jessica Y Islam; Amir Alishahi Tabriz; Wenbin Zhang; Thomas J Dilling
Journal:  Radiother Oncol       Date:  2021-12-23       Impact factor: 6.280

Review 7.  Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients.

Authors:  Noman Paracha; Ahmed Abdulla; Katherine S MacGilchrist
Journal:  Health Qual Life Outcomes       Date:  2018-09-12       Impact factor: 3.186

8.  Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory.

Authors:  Tito Mendoza; Ajay Sheshadri; Mehmet Altan; Kenneth Hess; Goldy George; Bettzy Stephen; Lilibeth Castillo; Enedelia Rodriguez; Jing Gong; Christine Peterson; Jordi Rodon Ahnert; Siqing Fu; Sarina A Piha-Paul; Shubham Pant; Ecaterina Dumbrava; Timonthy A Yap; Filip Janku; Apostolia M Tsimberidou; Vivek Subbiah; Daniel D Karp; Abdulrazzak Zarifa; Lacey M McQuinn; Charles Cleeland; David S Hong; Aung Naing
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.